Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Support

This educational activity is supported by educational grants from Daiichi Sankyo, Inc., and Genentech, Inc.

Enduring CME Activity From the July 6, 2020, Live Webcast: COVID-19 and Cancer Care: What Oncologists Need to Know Today – Focus on Treating Patients with Lung Cancer

Release Date: July 15, 2020
Expiration Date: July 15, 2021

Activity Overview

The novel coronavirus that causes coronavirus disease 2019 (COVID-19) has rapidly become one of the most challenging public health crises in modern history. With millions of confirmed infections worldwide, including more than 3 million cases in the United States (as of July 13, 2020), this virus has the potential to infect individuals of all ages.

However, older individuals and patients with underlying health conditions, including cardiovascular disease, diabetes, and pulmonary disorders, seem to be the most vulnerable to infection and to developing more severe illness. Patients with cancer must also be considered in this vulnerable and high-risk population.

But how is this pandemic specifically affecting cancer care, and what do clinicians need to know today to ensure they are providing the best care to their patients with cancer?

This enduring CME activity is an archive of the live broadcast from July 6, 2020, featuring 4 oncologists who addressed the rapidly evolving issues clinicians face when treating patients with lung cancer.

Acknowledgement of Support

This educational activity is supported by educational grants from Daiichi Sankyo, Inc., and Genentech, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward oncologists, surgeons, radiation oncologists, infectious disease specialists, primary care physicians, nurses, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the care of patients with cancer.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Discuss the risk of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the severity of illness with COVID-19 across the populations of patients with lung cancer
  • Identify optimal protocols for cancer facilities, in both the inpatient and outpatient settings, to help minimize the risk of coronavirus infection
  • Assess strategies to optimize treatment protocols for patients with lung cancer in light of the current COVID-19 pandemic

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Heather A. Wakelee, MD
Heather A. Wakelee, MD
Professor of Medicine (Oncology)
Stanford University Medical Center
Stanford, CA

Disclosures: Grant/Research Support: Genentech/Roche, Pfizer, Lilly, Celgene, Exelixis, Novartis, Clovis Oncology, Xcovery, Bristol Myers Squibb, Merck, Arrys; Consultant: Mirati Therapeutics, Helsinn; Stock/Shareholder: COTA; Other Support: Steering committee participation/Unpaid Advisor: Genentech/Roche, Merck, Cellworks.


Jamie E. Chaft, MD
Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Bristol Myers Squibb, AstraZeneca, Genentech, Merck; Consultant: Bristol Myers Squibb, AstraZeneca, Merck, Genentech.

Lecia V. Sequist, MD
Lecia V. Sequist, MD
Director, Center for Innovation in Early Cancer Detection
The Landry Family Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA

Disclosures: Grant/Research Support: Novartis, AstraZeneca, Genentech, Boehringer-Ingelheim; Consultant: AstraZeneca, Genentech, Flagship.

Cardinale B. Smith, MD, PhD
Cardinale B. Smith, MD, PhD
Associate Professor, Medicine, Hematology and Medical Oncology
Associate Professor, Geriatrics and Palliative Medicine
Icahn School of Medicine at Mount Sinai
Chief Quality Officer, Cancer Services, Mount Sinai Health System
Division of Hematology/Medical Oncology and Brookdale Department of Geriatrics and Palliative Medicine
New York, NY

Disclosures: Consultant: Teva Pharmaceuticals.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By